Shares of cancer screening and diagnostic tests provider Exact Sciences Corporation (EXAS) are rising more than 17% Tuesday morning after the company said it has agreed to buy Thrive Earlier Detection Corp. for about $2.15 billion, cash and stock.
Thrive Earlier Detection Corp. is a healthcare company focused on incorporating earlier cancer detection into routine medical care.
The deal is expected to close during the first quarter of 2021.
The Exact Sciences shares touched a new high of $125.78 this morning.
For comments and feedback: editorial@rttnews.com